Grant: Collaborative Health Research Projects
University of Toronto
$144,757.00
Stem cell counting: Development and application
FY 2013-14
Summary
The stem cells of the blood-forming system (hematopoietic stem cells, HSCs) are rare, comprising only 1 in every 20,000 bone marrow cells. Because they are the only cell in marrow with the capacity to sustain blood cell production throughout adult life, they play a central role in many blood cell disorders and most leukemias. They are also the principal therapeutic entity responsible for the regenerative effectiveness of marrow or cord blood transplants. There is accordingly a need to be able to enumerate them in many circumstances of practical clinical importance. Outcomes of clinical HSC transplants, for example to treat blood diseases such as leukemia, depend critically on the number of HSCs in the donor sample. Unfortunately, there presently exists no practical means of counting HSCs directly. Instead, researchers that need to enumerate them must resort to extremely cumbersome and expensive assays that involve injecting the cells into mice and then waiting a minimum of 5 months before obtaining a result. The enormous effort, time and cost it takes to enumerate HSCs are major limiting factors in blood stem cell research and clinical practice.We propose here the development of a technology for direct and rapid marker-based enumeration of HSCs within half a day, in any cellular sample regardless of biological state and without requirement for prior enrichment. Our proposal brings together a multidisciplinary team of world experts in the fields of stem cell bioengineering (Zandstra), materials and microfluidics (Kumacheva), stem cell biology (Iscove) and single-cell cytometry (Audet). The anticipated outcome will be a high-throughput microfluidics automatable system (Stem Cell Counting Chip - SCCC) which will be translated, with the help of Centre for the Commercialization of Regenerative Medicine and STEMCELL Technologies, into a device usable in any hospital for the robust enumeration of rare cell types such as HSCs. We expect the SCCC to revolutionize stem cell research and regenerative medicine by providing the tools to enumerate HSCs in donor samples or in patients, in real time.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
414056-2012
Name nom
Zandstra, Peter
Department département
Biomaterials and Biomedical Engineering, Inst. of (IBBME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2012
Award amount
144757
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
2 & 3
Nb partie
3
Application title
Stem cell counting: Development and application
Keyword
NSERC
Application summary
The stem cells of the blood-forming system (hematopoietic stem cells, HSCs) are rare, comprising only 1 in every 20,000 bone marrow cells. Because they are the only cell in marrow with the capacity to sustain blood cell production throughout adult life, they play a central role in many blood cell disorders and most leukemias. They are also the principal therapeutic entity responsible for the regenerative effectiveness of marrow or cord blood transplants. There is accordingly a need to be able to enumerate them in many circumstances of practical clinical importance. Outcomes of clinical HSC transplants, for example to treat blood diseases such as leukemia, depend critically on the number of HSCs in the donor sample. Unfortunately, there presently exists no practical means of counting HSCs directly. Instead, researchers that need to enumerate them must resort to extremely cumbersome and expensive assays that involve injecting the cells into mice and then waiting a minimum of 5 months before obtaining a result. The enormous effort, time and cost it takes to enumerate HSCs are major limiting factors in blood stem cell research and clinical practice.We propose here the development of a technology for direct and rapid marker-based enumeration of HSCs within half a day, in any cellular sample regardless of biological state and without requirement for prior enrichment. Our proposal brings together a multidisciplinary team of world experts in the fields of stem cell bioengineering (Zandstra), materials and microfluidics (Kumacheva), stem cell biology (Iscove) and single-cell cytometry (Audet). The anticipated outcome will be a high-throughput microfluidics automatable system (Stem Cell Counting Chip - SCCC) which will be translated, with the help of Centre for the Commercialization of Regenerative Medicine and STEMCELL Technologies, into a device usable in any hospital for the robust enumeration of rare cell types such as HSCs. We expect the SCCC to revolutionize stem cell research and regenerative medicine by providing the tools to enumerate HSCs in donor samples or in patients, in real time.